On Aug. 24, 2017, Adamas announced U.S. Food and Drug Administration (FDA) approval of GOCOVRI as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients.

GOCOVRI is a high dose 274 mg amantadine (equivalent to 340 mg amantadine HCl) taken once-daily at bedtime that delivers consistently high levels of amantadine from the morning and throughout the day when dyskinesia occurs.